CLINICAL TRIALS PROFILE FOR NESACAINE
✉ Email this page to a colleague
All Clinical Trials for NESACAINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00845962 ↗ | A Comparison of Bupivacaine and 2-chloroprocaine for Spinal Anesthesia | Completed | Centre hospitalier de l'Université de Montréal (CHUM) | N/A | 2009-02-01 | The purpose of this study is to compare the efficacity and the readiness for discharge between two local anesthetics, bupivacaine and 2-chloroprocaine, used for spinal anesthesia. |
| NCT00845962 ↗ | A Comparison of Bupivacaine and 2-chloroprocaine for Spinal Anesthesia | Completed | Université de Montréal | N/A | 2009-02-01 | The purpose of this study is to compare the efficacity and the readiness for discharge between two local anesthetics, bupivacaine and 2-chloroprocaine, used for spinal anesthesia. |
| NCT02862912 ↗ | Chloroprocaine Spinal Anesthesia for Cervical Cerclage (CP Spinal) | Completed | Columbia University | Phase 4 | 2016-11-08 | This study aims to determine whether or not spinal anesthesia with the local anesthetic drug, chloroprocaine, wears off faster than the local anesthetic drug, bupivacaine, and results in faster discharge from the post-anesthesia care unit after surgery. |
| NCT03260972 ↗ | Intraabdominal Chloroprocaine During Cesarean Delivery for Pain Control | Withdrawn | Johns Hopkins University | Phase 3 | 2021-06-01 | Objective The objective of this study is to test the hypothesis that instillation of intra-abdominal chloroprocaine during cesarean deliveries is associated with decreased postoperative pain and nausea compared to placebo, without increasing intraoperative and postoperative complications. Methods The investigators plan to randomize about 150 women undergoing primary and repeat cesarean deliveries to intra-abdominal chloroprocaine versus placebo prior to abdominal closure. Women will be excluded if they have ascertained or presumptive hypersensitivity to the ester type and major anesthetics; if they have chronic pelvic pain or if they refuse to participate in the study. The investigators' primary outcome measure will be postoperative pain as measured by visual analogue scale (VAS) at 1 hour after skin closure. Secondary outcomes will include objective pain as measured by VAS at 2, 6, 24 and 48 hours at rest and during mobilization, adverse effects of chloroprocaine (gastrointestinal side effects, pruritus), concomitant analgesic requirement, hospital readmissions and length of hospital stay. Analysis will follow the intention-to-treat principle. The investigators will also be studying the concentration/effect (PKPD) relationship of chloroprocaine use for pain control in the postpartum period. The time courses of the plasma concentrations of chloroprocaine will be analyzed with mixed effects pharmacokinetic-pharmacodynamic (PKPD). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NESACAINE
Condition Name
Clinical Trial Locations for NESACAINE
Trials by Country
Clinical Trial Progress for NESACAINE
Clinical Trial Phase
Clinical Trial Sponsors for NESACAINE
Sponsor Name
